<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hydatidiform mole: Treatment and follow-up</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hydatidiform mole: Treatment and follow-up</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hydatidiform mole: Treatment and follow-up</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ross S Berkowitz, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Neil S Horowitz, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin M Elias, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 08, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hydatidiform mole (HM) is one of a group of diseases that develop from abnormal proliferation of trophoblasts and are classified as gestational trophoblastic disease (GTD). The two distinct types of HM, complete mole and partial mole, have different karyotypes, gross and microscopic histopathology, clinical presentations, and prognoses [<a href="#rid1">1-3</a>]. Management is similar but with some differences.</p><p>Treatment involves surgical removal of the molar pregnancy followed by surveillance of serial human chorionic gonadotropin (hCG) levels to confirm resolution of disease or to identify development of gestational trophoblastic neoplasia (GTN), which includes invasive mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor. Although GTN is the invasive or metastatic form of GTD, it has an excellent cure rate with chemotherapy [<a href="#rid1">1-4</a>].</p><p>The treatment and follow-up of HM will be discussed here. The clinical findings, pathology, and diagnostic evaluation of HM and issues related to GTN are reviewed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3243.html" rel="external">"Hydatidiform mole: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3230.html" rel="external">"Gestational trophoblastic disease: Pathology"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/95881.html" rel="external">"Gestational trophoblastic neoplasia: Epidemiology, clinical features, diagnosis, staging, and risk stratification", section on 'Differential diagnosis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3242.html" rel="external">"Initial management of low-risk gestational trophoblastic neoplasia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/96232.html" rel="external">"Initial management of high-risk gestational trophoblastic neoplasia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/96235.html" rel="external">"Management of resistant or recurrent gestational trophoblastic neoplasia"</a>.)</p><p></p><p class="headingAnchor" id="H432805321"><span class="h1">CHOICE OF PROCEDURE FOR REMOVAL OF MOLAR TISSUE</span><span class="headingEndMark"> — </span>Surgical removal of the HM is the central component of treatment and can be accomplished by either uterine evacuation or hysterectomy. We suggest surgical uterine evacuation for most patients because it is effective, preserves childbearing capacity, and is less morbid.</p><p>Hysterectomy is a reasonable alternative for patients who have completed childbearing, particularly those with a known or presumptive complete mole and the following risk factors for gestational trophoblastic neoplasia (GTN) (see <a class="local">'Frequency of gestational trophoblastic neoplasia after molar pregnancy'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Signs of excessive trophoblastic proliferation (eg, uterine size greater than gestational age, serum human chorionic gonadotropin [hCG] levels &gt;100,000 milli-international units/mL, ovarian theca lutein cysts &gt;6 cm in diameter).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of myometrial invasion on diagnostic imaging studies [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/95881.html" rel="external">"Gestational trophoblastic neoplasia: Epidemiology, clinical features, diagnosis, staging, and risk stratification", section on 'Imaging studies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;40 years [<a href="#rid6">6,7</a>].</p><p></p><p>Hysterectomy eliminates any locally invasive disease at the time of initial treatment of HM and reduces the chance of developing GTN, but does not prevent all cases of metastatic disease because some patients have occult metastases before the procedure [<a href="#rid8">8</a>]. In a meta-analysis including six retrospective studies (291 patients) evaluating the incidence of postmolar GTN in patients &gt;40 years, patients undergoing total hysterectomy compared with uterine evacuation had lower rates of postmolar GTN (odds ratio [OR] 0.19, 95% CI 0.08-0.48) [<a href="#rid9">9</a>]. </p><p>Medication-only methods of uterine evacuation (<a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a>, <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a>, <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">oxytocin</a>) should not be used, although data are limited. The only study that evaluated this approach reported that 20 of 77 cases (26 percent) subsequently required surgical evacuation (suction or sharp curettage) for persisting symptoms, persistently raised hCG levels, or a combination of symptoms and raised hCG [<a href="#rid10">10</a>]. In addition, medical evacuation was associated with a higher rate of subsequent need for chemotherapy than was surgical evacuation (9.1 versus 3.8 to 5.9 percent).</p><p class="headingAnchor" id="H830260002"><span class="h1">PATIENT PREPARATION</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>RhD-negative patients</strong> – Patients who are RhD-negative should receive <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">anti-D immune globulin</a> at the time of treatment. A complete mole does not contain fetal red cells, but prophylaxis after evacuation is suggested because fetal red cells are present in partial molar pregnancies. In addition, sometimes it is initially difficult to determine whether the patient had a molar pregnancy, a missed abortion, or a partial mole with fetal absorption. (See  <a class="medical medical_review" href="/z/d/html/6773.html" rel="external">"RhD alloimmunization: Prevention in pregnant and postpartum patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperthyroidism and preeclampsia</strong> – Hyperthyroidism and preeclampsia may occur in patients with HM. However, as complete mole is usually detected in the first trimester, and these conditions do not usually present until the second trimester, they are infrequently seen.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Symptomatic hyperthyroidism</strong> – Although hyperthyroidism due to gestational trophoblastic disease resolves with treatment of the HM and subsequent normalization of human chorionic gonadotropin (hCG) levels, symptomatic patients require treatment with a beta blocker prior to surgery [<a href="#rid11">11</a>]. The longer acting beta blockers (eg, <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a>) are preferred because an oral dose taken one hour before surgery will usually maintain adequate beta blockade until the patient is able to take oral medications postoperatively. We typically start with atenolol 25 to 50 mg daily and increase the dose, as needed, to maintain the pulse rate below 80 beats/minute; up to 200 mg daily may be needed for the symptomatic treatment of hyperthyroidism and control of tachycardia.</p><p></p><p class="bulletIndent2">Intravenous <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> (0.5 to 1 mg over 10 minutes followed by 1 to 2 mg over 10 minutes every few hours) can be used to control fever, hypertension, and tachycardia intraoperatively. However, patients with possible thyroid storm are at risk for acute respiratory distress syndrome and pulmonary hypertension and procedures should only be performed with a secure airway in place [<a href="#rid12">12</a>]. </p><p></p><p class="bulletIndent2">Beta blockers should be continued until the patient's thyroid disease is under control. (See  <a class="medical medical_review" href="/z/d/html/7858.html" rel="external">"Nonthyroid surgery in the patient with thyroid disease", section on 'Beta blockers'</a>.)</p><p></p><p class="bulletIndent2">Some patients may require thionamides. (See  <a class="medical medical_review" href="/z/d/html/7884.html" rel="external">"Hyperthyroidism during pregnancy: Treatment", section on 'Therapeutic options'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preeclampsia</strong> – Preeclampsia associated with HM resolves promptly after molar evacuation and usually does not require medical management, unless severe features of the disease are present. For example, severe hypertension, if present, should be treated to reduce the risk of stroke. Eclampsia is rare; the decision to administer <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">magnesium sulfate</a> for seizure prophylaxis should be individualized [<a href="#rid13">13,14</a>]. (See  <a class="medical medical_review" href="/z/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'Acute therapy of severe hypertension'</a> and  <a class="medical medical_review" href="/z/d/html/139247.html" rel="external">"Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Candidates for seizure prophylaxis'</a>.)</p><p></p><p class="headingAnchor" id="H2649151769"><span class="h1">PROCEDURES</span></p><p class="headingAnchor" id="H20921491"><span class="h2">Uterine evacuation</span><span class="headingEndMark"> — </span>Uterine evacuation consists of mechanical dilation of the cervix, followed by suction aspiration (regardless of uterine size), and then sharp curettage to help assure complete evacuation of molar tissue. Electric and manual suction evacuation are comparable in terms of their effectiveness for complete evacuation and in side effects [<a href="#rid15">15,16</a>]. The technique is the same as for pregnancy termination. Use of ultrasound guidance is recommended to ensure complete evacuation of uterine contents [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/3287.html" rel="external">"First-trimester pregnancy termination: Uterine aspiration"</a> and  <a class="medical medical_review" href="/z/d/html/104595.html" rel="external">"Second-trimester pregnancy termination: Dilation and evacuation"</a>.)</p><p>We do not use osmotic dilators, but some clinicians insert them in nulliparas on the day before the procedure to facilitate dilation (see  <a class="medical medical_review" href="/z/d/html/111284.html" rel="external">"Pregnancy termination: Cervical preparation for procedural abortion"</a>). Medications (eg, prostaglandins) are not used for cervical ripening because their use delays the procedure, they are associated with side effects, they may increase the risk of complications, and they do not confer proven benefit [<a href="#rid10">10</a>].</p><p>At the time of anesthesia induction, an <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">oxytocin</a> infusion (10 units in 1 L <a class="drug drug_general" data-topicid="108196" href="/z/d/drug information/108196.html" rel="external">Lactated Ringer</a> solution at 50 drops/minute) is begun to promote myometrial contraction and thus decrease blood loss.</p><p>Mechanical dilation of the cervix is performed gradually until a cannula diameter appropriate for the uterine size can be inserted. Most clinicians choose a diameter equal to or 1 mm smaller than the number of weeks of gestation of a similarly sized normal intrauterine pregnancy.</p><p>Disruption of the HM can cause brisk bleeding. Although the uterus generally shrinks rapidly as the contents are aspirated and <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">oxytocin</a> is infused, which diminishes blood loss, bleeding is typically substantially more than that encountered during evacuation of a pregnancy. Transabdominal fundal massage can facilitate uterine contraction if the uterus is sufficiently above the pelvic brim (≥14 week size). However, hysterectomy or uterine artery embolization may be needed for emergency management of acute hemorrhage [<a href="#rid18">18</a>]. As the risk of bleeding increases with uterine size, blood for transfusion should be available when the uterus is larger than a first trimester gestation.</p><p>When suction evacuation is believed to be complete, gentle sharp curettage should be performed to remove any residual molar tissue [<a href="#rid19">19</a>]. Intraoperative sonography can be used to monitor the procedure and help determine when evacuation is complete.</p><p>The evacuated tissue should be inspected at the end of the procedure. Complete molar tissue usually will have markedly dilated villi that appear like grape clusters. The changes in partial mole are usually more subtle, and partial mole may only be suspected or diagnosed based upon the microscopic findings. In select cases when clinical or sonographic findings suggest the initial uterine curettage was incomplete, a second uterine curettage may be performed to remove retained molar tissue. However, second curettage may not lower the risk of developing gestational trophoblastic neoplasia (GTN). In a retrospective study including 173 patients with HM in Japan, patients undergoing routine second curettage compared with second curettage only for molar remnants had similar rates of GTN [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H1265191263"><span class="h2">Hysterectomy</span><span class="headingEndMark"> — </span>Hysterectomy can be safely performed by either an abdominal or laparoscopic approach; the choice is influenced by technical issues such as uterine size and the clinician's familiarity with the techniques [<a href="#rid21">21</a>]. Uterine artery embolization prior to hysterectomy (to reduce intraoperative blood loss) and laparoscopic hysterectomy in combination with dilation and evacuation (to reduce uterine size and avoid laparotomy) have also been described [<a href="#rid22">22,23</a>]. (See  <a class="medical medical_review" href="/z/d/html/3272.html" rel="external">"Hysterectomy (benign indications): Selection of surgical route"</a>.)</p><p>Preoperative issues (eg, thromboprophylaxis, prophylactic antibiotics, elective oophorectomy) are similar to those before any abdominal or laparoscopic hysterectomy for benign uterine disease, except for administration of <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">anti-D immune globulin</a> in D-negative patients. Due to the highly vascular nature of the gravid uterus, supracervical hysterectomy may be performed to reduce blood loss and avoid ureteral injury. (See  <a class="medical medical_review" href="/z/d/html/3311.html" rel="external">"Hysterectomy: Abdominal (open) route"</a> and  <a class="medical medical_review" href="/z/d/html/3286.html" rel="external">"Hysterectomy: Laparoscopic"</a>.)</p><p>If prominent ovarian theca lutein cysts are present and symptomatic (large cysts can cause troublesome pressure symptoms), they can be aspirated to reduce the volume and patient discomfort.</p><p>The ovaries may be left in situ since ovarian metastases are rarely encountered.</p><p class="headingAnchor" id="H2118015991"><span class="h1">POSTEVACUATION COMPLICATIONS</span></p><p class="headingAnchor" id="H587576190"><span class="h2">Cardiopulmonary symptoms</span><span class="headingEndMark"> — </span>In patients treated in the first trimester, postoperative cardiopulmonary symptoms are rare [<a href="#rid24">24,25</a>]. In the second trimester, approximately 2 percent of patients treated by evacuation develop cardiopulmonary symptoms, including chest pain, dyspnea, tachypnea, and tachycardia [<a href="#rid24">24</a>]. Respiratory distress after uterine evacuation is usually attributed to trophoblastic embolization. Respiratory problems can also be due to massive fluid replacement, complications of thyroid storm, or preeclampsia and can develop in patients who undergo hysterectomy.</p><p>Auscultation of the chest usually reveals diffuse rales, and the chest radiograph often demonstrates bilateral pulmonary infiltrates, which have been misinterpreted as metastases. With standard cardiopulmonary support, the infiltrates resolve in most cases over 48 to 72 hours as the human chorionic gonadotropin (hCG) level decreases since complications of complete mole (eg, hyperthyroidism, preeclampsia) are strongly associated with marked trophoblastic proliferation and high hCG values [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H3149841609"><span class="h2">Ovarian theca lutein cysts</span><span class="headingEndMark"> — </span>Theca lutein cysts usually regress slowly over two to four months following evacuation as hCG levels decline. Large cysts causing troublesome pressure symptoms can be aspirated transabdominally under ultrasound guidance.</p><p>Theca lutein cysts may cause adnexal torsion or, rarely, they rupture spontaneously. In such cases, they can be managed laparoscopically [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/3305.html" rel="external">"Ovarian and fallopian tube torsion"</a> and  <a class="medical medical_review" href="/z/d/html/3298.html" rel="external">"Evaluation and management of ruptured ovarian cyst"</a>.)</p><p class="headingAnchor" id="H664827815"><span class="h1">USE OF PROPHYLACTIC CHEMOTHERAPY</span><span class="headingEndMark"> — </span>We rarely administer prophylactic chemotherapy around the time of molar evacuation. Prophylactic chemotherapy has been evaluated as a method to reduce the risk of development of gestational trophoblastic neoplasia (GTN), but supporting data are weak, and prophylactic chemotherapy may increase drug resistance and is associated with toxicities (see <a class="local">'Frequency of gestational trophoblastic neoplasia after molar pregnancy'</a> below). We only consider it in patients who have a complete mole and <strong>all</strong> of the following: </p><p class="bulletIndent1"><span class="glyph">●</span>Treated by evacuation rather than hysterectomy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High risk of developing GTN (ie, they have signs of trophoblastic proliferation, uterine size greater than gestational age, serum human chorionic gonadotropin [hCG] levels &gt;100,000 milli-international units/mL, and ovarian theca lutein cysts &gt;6 cm in diameter, and are age &gt;40 years). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>hCG follow-up is either unavailable or unreliable, which is a particular consideration in global areas that are resource-limited. </p><p></p><p>In a 2017 meta-analysis of patients with complete moles (three randomized trials, 613 patients), use of prophylactic chemotherapy resulted in a 63 percent reduction in GTN (relative risk [RR] 0.37, 95% CI 0.24-0.57) [<a href="#rid28">28</a>]. Two trials were of poor methodologic quality. When only the small, well-conducted trial in 59 high-risk patients was analyzed, the reduction remained statistically significant but with a wide confidence interval (RR 0.28, 95% CI 0.1-0.73). However, the overall benefit of prophylactic chemotherapy was not clear because, among patients who were subsequently diagnosed with GTN, those who had received prior prophylactic chemotherapy experienced a one-month delay in subsequent diagnosis and required an additional cycle of chemotherapy to achieve remission of GTN relative to those who had not received prophylactic chemotherapy. In a subsequent randomized trial of 76 patients with complete moles, those treated with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (100 mg as a single intramuscular injection; 34 patients) compared with standard of care had normalization of hCG five weeks earlier (9.7 versus 14.7 weeks); all patients achieved hCG normalization [<a href="#rid29">29</a>]. The authors suggested that the reduced surveillance time was an advantage in areas with limited resources. </p><p>Both <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and actinomycin D have been used for chemoprophylaxis; no data are available to suggest whether one is superior to the other. At our center, we generally administer actinomycin D when prophylaxis is indicated. Chemoprophylaxis does not appear to impact future fertility potential [<a href="#rid30">30,31</a>]. Dosing and side effects are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/3242.html" rel="external">"Initial management of low-risk gestational trophoblastic neoplasia", section on 'Methotrexate as the preferred option'</a> and  <a class="medical medical_review" href="/z/d/html/3242.html" rel="external">"Initial management of low-risk gestational trophoblastic neoplasia", section on 'Alternatives including dactinomycin and other agents'</a>.)</p><p class="headingAnchor" id="H20921529"><span class="h1">POSTOPERATIVE MONITORING</span><span class="headingEndMark"> — </span>Postoperative human chorionic gonadotropin (hCG) monitoring is performed<strong> </strong>to detect<strong> </strong>development of<strong> </strong>gestational trophoblastic neoplasia (GTN), which is indicated by an hCG level that does not return to undetectable. Persistent hCG elevation is usually due to molar tissue that invaded the myometrium (ie, invasive mole) and thus was not completely removed by aspiration and curettage, but a small proportion are due to metastatic invasive mole. Occasionally, persistent hCG elevation is due to development of choriocarcinoma and, very rarely, to development of placental site trophoblastic tumor or epithelioid trophoblastic tumor.</p><p>Poor compliance with postevacuation surveillance and treatment protocols is associated with poorer outcomes due to advanced disease. In the United States, indigent patients treated at urban, public hospitals are the group most likely to fail to comply with standard protocols for a number of reasons, including cost, transportation issues, and childcare requirements [<a href="#rid32">32</a>]. Patient education is crucial to help patients understand and comply with surveillance protocols. Internet resources can substantially contribute to a patient's understanding of gestational trophoblastic disease (GTD) and support compliance with treatment recommendations [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H1137849053"><span class="h2">Contraception during monitoring</span><span class="headingEndMark"> — </span>Patients with HM must be advised to use reliable contraception during the entire period of postoperative hCG monitoring. A new pregnancy during this time would make it difficult or impossible to interpret hCG results and would complicate management. Options include hormonal contraception (progestin-only or combined estrogen-progestin) or barrier methods [<a href="#rid34">34,35</a>]. Oral contraceptives after molar evacuation as compared with barrier methods do not increase the risk for or clinical aggressiveness of GTN when adjusted for risk factors. </p><p>For patients with confirmed intrauterine disease and persistently elevated hCG levels, the Centers for Disease Control and Prevention recommends <strong>not</strong> inserting an intrauterine device (IUD) because of theoretical risk for perforation, infection, and hemorrhage [<a href="#rid34">34</a>]. An IUD may be used in patients with confirmed GTD and undetectable or decreasing hCG levels. For patients with suspected intrauterine disease, an IUD should be used with caution, and in our practice, we suggest that other forms of contraception (eg, combined estrogen-progestin, barrier methods) be more strongly considered. </p><p class="headingAnchor" id="H188883990"><span class="h2">Protocol for serial hCG measurements</span><span class="headingEndMark"> — </span>After surgical treatment of HM (evacuation or hysterectomy), measurements of serum hCG levels are obtained weekly in all patients until either the level remains undetectable or criteria are met for an increasing or plateaued level, as described below. Our approach is shown in the algorithm  (<a class="graphic graphic_algorithm graphicRef105721" href="/z/d/graphic/105721.html" rel="external">algorithm 1</a>). (See <a class="local">'Interpretation and management of hCG levels during monitoring'</a> below.)</p><p>The hCG assay should measure the intact hCG dimer as well as its various subunits and fragments, which are increased in GTD compared with normal pregnancy. (See  <a class="medical medical_review" href="/z/d/html/3209.html" rel="external">"Human chorionic gonadotropin: Biochemistry and measurement in pregnancy and disease"</a>.)</p><p class="headingAnchor" id="H704367010"><span class="h2">Interpretation and management of hCG levels during monitoring</span></p><p class="headingAnchor" id="H311143745"><span class="h3">Decreasing and undetectable hCG levels</span><span class="headingEndMark"> — </span>A decreasing hCG level is defined as a level that progressively decreases &gt;10 percent across four values during a three-week period (eg, on days 1, 7, 14, and 21).</p><p>When the hCG level becomes undetectable, the risk of developing GTN in patients with a partial mole or complete mole is much less than 1 percent and is lower for partial mole than complete mole [<a href="#rid36">36-45</a>]. Therefore, in patients with complete mole, after one normal hCG, we obtain monthly hCG values for three additional months and then discontinue monitoring if the level remains undetectable. In patients with partial mole, after hCG normalizes, we obtain a single additional hCG measurement one month later and then discontinue monitoring if the level remains undetectable  (<a class="graphic graphic_algorithm graphicRef105721" href="/z/d/graphic/105721.html" rel="external">algorithm 1</a>).</p><p>The International Federation of Gynecology and Obstetrics (FIGO) recommends following patients with molar pregnancies with hCG levels every one to two weeks until hCG normalization and then monthly [<a href="#rid46">46</a>]. In patients with a partial mole, if a normal hCG is confirmed one month after the hCG normalized, then hCG monitoring can be discontinued; in patients with a complete mole, confirmatory normal hCG levels are needed for six months before discontinuing hCG monitoring. National Comprehensive Cancer Network (NCCN) guidelines also suggest following hCG levels every one to two weeks [<a href="#rid47">47</a>]. When three consecutive hCG levels are normal, two additional hCG assays should be obtained every three months, with discontinuation of hCG monitoring if the hCG remains normal.</p><p>These approaches are based, in part, on data from a study of molar pregnancy from Charing Cross Hospital in England that showed in patients with a complete mole (8400 patients), the risk of GTN at zero, four, and seven months from the point of hCG normalization was 1 in 406, 1 in 839, and 1 in 932, respectively [<a href="#rid45">45</a>]. For patients with a partial mole (9586 patients), the risk was 1 in 3195, 1 in 4793, and 1 in 9584, respectively. The rapidity of hCG normalization was predictive of the likelihood of resolution versus development of GTN. In patients with a complete mole, normalization within 56 days of evacuation reduced the risk of GTN to approximately 1 in 1159 versus 1 in 308 when normalization occurred after 56 days. A trend in reduction with rapid normalization was also observed in patients with a partial mole: 1 in 4002 versus 1 in 2792. In another study of patients with a complete mole, hCG levels &lt;200 milli-international units/mL in the fourth week after evacuation or &lt;100 milli-international units/mL in the sixth week after evacuation had a risk of persistence &lt;9 percent, whereas an hCG level &gt;2000 milli-international units/mL in the fourth week was associated with a 64 percent risk [<a href="#rid36">36</a>]. In a study of patients with a partial mole, an hCG level &gt;199 milli-international units/mL in the third through eighth weeks following evacuation was associated with at least a 35 percent risk of GTN [<a href="#rid48">48</a>]. hCG regression after molar evacuation does not appear to be influenced by patient’s age, race, ethnicity, body mass index, or hormonal contraception use [<a href="#rid49">49</a>]. </p><p>In a meta-analysis dominated by data from Charing Cross Hospital described above [<a href="#rid45">45</a>], the overall risk of GTN after normalization of the hCG was 0.35 percent after a complete mole and 0.03 percent after a partial mole [<a href="#rid50">50</a>]. Among GTN cases after normalization of hCG level following complete mole, 90 percent occurred when the time from evacuation to normalization was ≥56 days, and 61 percent occurred beyond FIGO's six-month surveillance period. These data support the safety of reducing the duration of hCG follow-up of molar pregnancies after hCG levels become undetectable and have prompted us to consider shortening our approach to surveillance of complete moles from three months to one monthly confirmatory hCG [<a href="#rid51">51</a>].</p><p>In some patients, the decrease in hCG level is slow, such that hCG levels remain detectable six months or more after postmolar evacuation. Although this pattern (decreasing hCG but still detectable at six months) used to be considered diagnostic of GTN, FIGO removed this criterion in 2018 due to findings in the following studies conducted in the United Kingdom and Brazil [<a href="#rid52">52,53</a>]. These patients can be managed conservatively (ie, continued hCG monitoring until levels meet criteria for undetectable, rising, or plateaued).</p><p class="bulletIndent1"><span class="glyph">●</span>In one study in which 76 of nearly 14,000 patients with an HM (complete 58 percent, partial 36 percent, unclassified 6 percent) had detectable hCG concentrations (range 5 to 887 international units/L) at 6 months after evacuation, 64 of 66 patients managed expectantly spontaneously achieved undetectable levels within 18 months of evacuation [<a href="#rid52">52</a>]. Of the remaining two patients managed expectantly, one was lost to follow-up but subsequently had a successful pregnancy and a normal hCG level, and the other had slightly raised hCG concentrations that were attributed to impaired renal clearance from end-stage kidney disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study in which 81 of over 12,000 patients with HM had persistent but falling hCG six months after evacuation (range 6 to 1750 international units/L), 80 percent managed expectantly spontaneously achieved undetectable levels [<a href="#rid53">53</a>].</p><p></p><p class="headingAnchor" id="H1482431284"><span class="h3">Increasing hCG levels</span><span class="headingEndMark"> — </span>An increasing hCG is defined as a level that progressively increases &gt;10 percent across three values during at least a two-week period (eg, on days 1, 7, and 14) [<a href="#rid54">54,55</a>]. Patients with this pattern meet criteria for postmolar GTN and typically require chemotherapy to achieve remission. The diagnostic evaluation, classification, staging, and treatment of postmolar GTN are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/95881.html" rel="external">"Gestational trophoblastic neoplasia: Epidemiology, clinical features, diagnosis, staging, and risk stratification"</a> and  <a class="medical medical_review" href="/z/d/html/3242.html" rel="external">"Initial management of low-risk gestational trophoblastic neoplasia"</a> and  <a class="medical medical_review" href="/z/d/html/96232.html" rel="external">"Initial management of high-risk gestational trophoblastic neoplasia"</a>.)</p><p class="headingAnchor" id="H937952858"><span class="h3">Plateaued hCG levels</span><span class="headingEndMark"> — </span>A plateaued hCG level is defined as four measurements that remain within ±10 percent over at least a three-week period (eg, days 1, 7, 14, and 21) [<a href="#rid54">54,55</a>]. Patients with this pattern meet criteria for postmolar GTN and typically require chemotherapy to achieve remission. The diagnostic evaluation, classification, staging, and treatment of postmolar GTN are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/95881.html" rel="external">"Gestational trophoblastic neoplasia: Epidemiology, clinical features, diagnosis, staging, and risk stratification"</a> and  <a class="medical medical_review" href="/z/d/html/3242.html" rel="external">"Initial management of low-risk gestational trophoblastic neoplasia"</a> and  <a class="medical medical_review" href="/z/d/html/96232.html" rel="external">"Initial management of high-risk gestational trophoblastic neoplasia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-level plateaued hCG (quiescent GTN)</strong> – On very rare occasions following molar evacuation, plateauing is due to quiescent GTN, which is defined as a low level (&lt;200 milli-international units/mL) of hCG that persists for at least three months after evacuation of an HM in the absence of any clinical or radiologic evidence of GTN. This condition is thought to be due to the presence of a small focus of highly differentiated, noninvasive syncytiotrophoblast cells that produce small amounts of hCG and usually do not progress to invasive disease as long as cytotrophoblast or intermediate cells are absent [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1">Patients with quiescent GTN do not require therapy but do require close follow-up because 6 to 10 percent will eventually develop active GTN, requiring treatment [<a href="#rid57">57-59</a>]. They should be monitored with monthly hCG testing and advised to avoid pregnancy [<a href="#rid56">56,60,61</a>].</p><p></p><p class="bulletIndent1">Because quiescent GTN is far less common than active GTN after a molar pregnancy, patients who develop a persistent plateau or elevation of hCG at low levels during HM follow-up may reasonably be diagnosed with active GTN and treated. Evidence of chemotherapy resistance (hCG level unresponsive to therapy presumably because the growth cycle of these cells is long and comparable to normal cells) combined with absence of any clinical or radiologic evidence of GTN supports the diagnosis of quiescent GTN and should prompt discontinuation of chemotherapy unless active GTN is documented by increasing hCG levels. Measurement of hyperglycosylated hCG (hCG-h) has been proposed for surveillance in patients with quiescent GTN [<a href="#rid58">58,60</a>]. Levels of hCG-h below 10 percent of total hCG would be consistent with quiescent GTN.</p><p></p><p class="bulletIndent1">There are several other etiologies of a persistent low-level hCG, including pituitary gland hCG production particularly in perimenopausal patients. The differential diagnosis of persistent low hCG is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3209.html" rel="external">"Human chorionic gonadotropin: Biochemistry and measurement in pregnancy and disease"</a>.)</p><p></p><p class="headingAnchor" id="H2593883694"><span class="h1">OUTCOME</span></p><p class="headingAnchor" id="H543309366"><span class="h2">Frequency of gestational trophoblastic neoplasia after molar pregnancy</span></p><p class="headingAnchor" id="H2776659529"><span class="h3">After a complete mole</span><span class="headingEndMark"> — </span>After a complete mole, approximately 15 to 20 percent of patients develop gestational trophoblastic neoplasia (GTN) [<a href="#rid50">50</a>]. Invasive disease is several-fold more common than metastatic disease [<a href="#rid50">50</a>].</p><p>As discussed above, signs of trophoblastic proliferation (uterine size greater than gestational age, serum human chorionic gonadotropin [hCG] levels &gt;100,000 milli-international units/mL, and ovarian theca lutein cysts &gt;6 cm in diameter) are a marker for high risk of development of GTN. In a study of 858 patients with complete HM from our center, the New England Trophoblastic Disease Center (NETDC), the presence versus absence of these signs was associated with higher rates of both uterine invasion (31 versus 3.4 percent) and metastases (8.8 versus 0.6 percent) [<a href="#rid62">62</a>].</p><p>Older age (&gt;40 years) is another high-risk factor for development of GTN. In patients over age 40, the risk may be 30 to 60 percent [<a href="#rid6">6,63,64</a>]. In patients over age 50, risks of 53 and 56 percent have been reported [<a href="#rid7">7,65</a>]. The reason that older age is a risk factor may be because complete moles are more commonly aneuploid in older patients, and aneuploidy may be a risk factor for GTN [<a href="#rid66">66,67</a>]. In comparison, adolescents (&lt;20 years of age) appear to have a low risk of developing GTN [<a href="#rid68">68</a>].</p><p>The combination of markedly elevated hCG levels &gt;175,000 milli-international units/mL and older age appears to constitute an "ultra high-risk" group: 11 of 13 patients (85 percent) ages 40 to 49 years with pre-evacuation hCG levels &gt;175,000 milli-international units/mL developed GTN in one study [<a href="#rid6">6</a>].</p><p>First-trimester versus second-trimester diagnosis does not impact the incidence of postmolar GTN [<a href="#rid24">24,25</a>].</p><p class="headingAnchor" id="H557441966"><span class="h3">After a partial mole</span><span class="headingEndMark"> — </span>After a partial mole, 1 to 5 percent of patients develop GTN [<a href="#rid50">50</a>]. Almost all patients with GTN have invasive disease; metastatic disease is rare. In 11 studies, including 7579 patients with partial mole, only 76 (1 percent) developed persistent tumor, and only nine (0.1 percent) had metastases [<a href="#rid1">1,2,69-77</a>].</p><p>While risk factors for GTN after partial molar pregnancy are less well defined, a study of 111 patients with partial molar pregnancy suggested an approximately twofold risk of developing GTN if the partial mole was the patient's first gestational event [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H543309434"><span class="h2">Obstetric outcomes of subsequent pregnancies</span><span class="headingEndMark"> — </span>In general, patients with either a complete or partial mole can anticipate normal future reproductive outcomes.</p><p>At the NETDC between 1965 and 2013, obstetric outcomes included the following [<a href="#rid79">79</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with a complete mole, there were 1388 subsequent pregnancies: 949 (68.4 percent) term live births, 103 (7.4 percent) premature deliveries, 7 (0.5 percent) stillbirths, 256 (18.4 percent) spontaneous abortions, and 11 (0.8 percent) ectopic pregnancies. Major and minor congenital anomalies were detected in 40 (3.8 percent) infants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with partial mole, there were 357 subsequent pregnancies: 260 (72.8 percent) term live births, 8 (2.2 percent) premature deliveries, 1 (0.3 percent) stillbirth, 64 (17.9 percent) spontaneous abortions, and 2 (0.6 percent) ectopic pregnancies. Major and minor congenital anomalies were diagnosed in only 4 (1.5 percent) infants.</p><p></p><p>Others have reported similar results [<a href="#rid80">80,81</a>].</p><p class="headingAnchor" id="H543315950"><span class="h2">Frequency of repeat molar pregnancy</span><span class="headingEndMark"> — </span>Patients with a prior HM are at increased risk of developing subsequent HM compared with the general population [<a href="#rid82">82</a>].</p><p>Estimates of the risk of subsequent HM are:</p><p class="bulletIndent1"><span class="glyph">●</span>After one molar pregnancy: 1 to 1.9 percent [<a href="#rid80">80,81,83</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After two molar pregnancies: 15 to 17.5 percent [<a href="#rid79">79,80</a>].</p><p></p><p>A single-institution series reported that, among 2578 patients with complete mole, the subsequent pregnancy was molar in 27 (1.9 percent), including 22 (81 percent) complete moles and 5 (19 percent) partial moles [<a href="#rid81">81</a>]. Among 2627 patients with a partial mole, the subsequent pregnancy was molar in 25 (1.7 percent), including 17 (68 percent) partial moles and 8 (32 percent) complete moles. The overall risk of molar pregnancy was 1.8 percent, which represented a 20-fold increase compared with the general population. Among 27 cases with repeat complete mole, 3 had later molar pregnancies, indicating a recurrence rate after two previous complete moles of 11 percent.</p><p>At the NETDC between 1965 and 2013, following two molar pregnancies, 25 patients had 40 subsequent pregnancies: 7 (17.5 percent) molar pregnancies (6 complete, 1 partial), 25 (62.5 percent) term live births, 1 intrauterine fetal demise (2.5 percent), 3 spontaneous abortions (7.5 percent), 3 induced abortions (7.5 percent), and 1 ectopic pregnancy (2.5 percent) [<a href="#rid79">79</a>].</p><p>Patients with repeat molar pregnancy are at an increased risk of developing GTN. One study reported a threefold increased risk of postmolar tumor in patients with a repeat molar pregnancy [<a href="#rid84">84</a>].<strong> </strong>Among 39 patients with two molar pregnancies managed at the NETDC from 1965 to 2013, persistent tumor developed following the first mole in 4 of 20 (20 percent) complete moles and following the second mole, in 8 of 20 (40 percent) complete moles, and in 2 of 17 (11.7 percent) partial moles [<a href="#rid79">79</a>].</p><p>Rare patients with molar pregnancy have mutations primarily in the <em>NLRP7</em> gene and, in some cases, the <em>KHDC3L</em> or <em>PADI6 </em>genes. These mutations can lead to a diploid biparental rather than the usual androgenetic molar pregnancy and predispose affected patients to recurrence. (See  <a class="medical medical_review" href="/z/d/html/3230.html" rel="external">"Gestational trophoblastic disease: Pathology", section on 'Genetics of molar pregnancy'</a> and  <a class="medical medical_review" href="/z/d/html/3243.html" rel="external">"Hydatidiform mole: Epidemiology, clinical features, and diagnosis", section on 'Familial recurrent molar pregnancy'</a>.)</p><p>Patients with a prior molar pregnancy should also be counseled that in vitro fertilization by intracytoplasmic sperm injection (ICSI) does not completely prevent recurrence. In a retrospective study of over 5400 patients with HM, 31 cases (0.6 percent) occurred after ICSI (26 singleton and 5 twin gestations) [<a href="#rid85">85</a>]. Those with HM following ICSI compared with spontaneous conception were diagnosed earlier (7 versus 10 weeks) and had a lower risk of GTN (adjusted odds ratio 0.22, 95% CI 0.05–0.93). This study also supports other data that GTN is higher in heterozygous compared with homozygous HM [<a href="#rid85">85-87</a>] .</p><p class="headingAnchor" id="H543314731"><span class="h1">OBSTETRIC MANAGEMENT OF SUBSEQUENT PREGNANCIES</span><span class="headingEndMark"> — </span>Due to the risk of recurrent HM, in our practice, we do the following in patients with a prior HM who become pregnant:</p><p class="bulletIndent1"><span class="glyph">●</span>First-trimester ultrasound to confirm normal gestational development.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After delivery, carefully examine the placenta and send to pathology for histologic examination if any gross abnormalities are present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Measure serum human chorionic gonadotropin (hCG) six weeks after the completion of any type of future pregnancy (eg, term delivery, miscarriage, pregnancy termination) to exclude choriocarcinoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Send all products of conception from miscarriages and pregnancy terminations for examination by a pathologist.</p><p></p><p class="headingAnchor" id="H2975476352"><span class="h1">SPECIAL CIRCUMSTANCES</span></p><p class="headingAnchor" id="H2425755715"><span class="h2">Multiple gestation</span><span class="headingEndMark"> — </span>In rare situations, molar gestations can arise as a multiple gestation, either a complete or partial mole and a viable fetus. These cases are challenging but, with expectant management, can lead to delivery of a live infant; the risk of GTN in these cases is approximately 50 percent [<a href="#rid88">88,89</a>]. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3243.html" rel="external">"Hydatidiform mole: Epidemiology, clinical features, and diagnosis"</a>.) </p><p class="headingAnchor" id="H591290936"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120644.html" rel="external">"Society guideline links: Gestational trophoblastic disease"</a>.)</p><p class="headingAnchor" id="H432807353"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical significance</strong> – Hydatidiform mole (HM) is part of a group of diseases classified as gestational trophoblastic disease (GTD), which originate from abnormal proliferation of trophoblast. The two distinct types of HM, complete mole and partial mole, have different karyotypes, gross and microscopic histopathology, clinical presentations, and prognoses. Gestational trophoblastic neoplasia (GTN) is the subtype of GTD that is invasive or metastatic and includes invasive mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of surgical procedure</strong> – Surgical removal of the HM is the central component of treatment and can be accomplished by either uterine evacuation or hysterectomy. For most patients, surgical uterine evacuation is preferred because it is effective, preserves childbearing capacity, and is less morbid. Hysterectomy is a reasonable alternative for patients who have completed childbearing, particularly those with risk factors for developing GTN. (See <a class="local">'Choice of procedure for removal of molar tissue'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of prophylactic chemotherapy</strong> – Prophylactic chemotherapy may reduce the risk of development of GTN, but supporting data are weak, and prophylactic chemotherapy may increase drug resistance and is associated with toxicities. We only consider it in patients with complete moles in whom follow-up with human chorionic gonadotropin (hCG) is either unavailable or unreliable, those being treated by evacuation rather than hysterectomy, <strong>and</strong> at high risk of developing GTN (ie, they have signs of trophoblastic proliferation, uterine size greater than gestational age, serum hCG levels &gt;100,000 milli-international units/mL, ovarian theca lutein cysts &gt;6 cm in diameter, and are age &gt;40 years). (See <a class="local">'Use of prophylactic chemotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative monitoring</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Serial hCG measurements</strong> – Following surgical treatment of HM, hCG levels are obtained until undetectable, plateaued, or rising levels are documented, as described in the algorithm  (<a class="graphic graphic_algorithm graphicRef105721" href="/z/d/graphic/105721.html" rel="external">algorithm 1</a>). A plateaued or rising level indicates GTN, which is treated with chemotherapy. (See <a class="local">'Protocol for serial hCG measurements'</a> above and <a class="local">'Interpretation and management of hCG levels during monitoring'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Contraception</strong> <strong>during monitoring</strong> – Patients with molar pregnancy should be advised to use reliable contraception during the entire interval of hCG monitoring. A new pregnancy during this period would make it difficult or impossible to interpret hCG results and would complicate management. Options include hormonal contraception (progestin-only or combined estrogen-progestin) or barrier methods. (See <a class="local">'Contraception during monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Frequency of GTN</strong> – After a complete mole, 15 to 20 percent of patients develop GTN; invasive disease is several-fold more common than metastatic disease. After a partial mole, 1 to 5 percent of patients develop GTN. Almost all of these patients have invasive disease; metastatic disease is rare. (See <a class="local">'Frequency of gestational trophoblastic neoplasia after molar pregnancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Future pregnancies</strong> <strong>and recurrence</strong> – In general, patients with either a complete or partial mole can anticipate normal future reproductive outcomes. Estimates of the risk of recurrent HM are 1 to 1.9 percent after one molar pregnancy and 15 to 17.5 percent after two molar pregnancies. (See <a class="local">'Obstetric outcomes of subsequent pregnancies'</a> above and <a class="local">'Frequency of repeat molar pregnancy'</a> above.)</p><p></p><p class="headingAnchor" id="H857076775"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Donald Peter Goldstein, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Vassilakos P, Riotton G, Kajii T. Hydatidiform mole: two entities. A morphologic and cytogenetic study with some clinical consideration. Am J Obstet Gynecol 1977; 127:167.</a></li><li><a class="nounderline abstract_t">Szulman AE, Surti U. The clinicopathologic profile of the partial hydatidiform mole. Obstet Gynecol 1982; 59:597.</a></li><li><a class="nounderline abstract_t">Szulman AE, Surti U. The syndromes of hydatidiform mole. I. Cytogenetic and morphologic correlations. Am J Obstet Gynecol 1978; 131:665.</a></li><li><a class="nounderline abstract_t">Berkowitz RS, Goldstein DP. Current advances in the management of gestational trophoblastic disease. Gynecol Oncol 2013; 128:3.</a></li><li><a class="nounderline abstract_t">von Welser SF, Grube M, Ortmann O. Invasive mole in a perimenopausal woman: a case report and systematic review. Arch Gynecol Obstet 2015; 292:1193.</a></li><li><a class="nounderline abstract_t">Elias KM, Shoni M, Bernstein M, et al. Complete hydatidiform mole in women aged 40 to 49 years. J Reprod Med 2012; 57:254.</a></li><li><a class="nounderline abstract_t">Elias KM, Goldstein DP, Berkowitz RS. Complete hydatidiform mole in women older than age 50. J Reprod Med 2010; 55:208.</a></li><li><a class="nounderline abstract_t">Lurain JR, Brewer JI, Torok EE, Halpern B. Natural history of hydatidiform mole after primary evacuation. Am J Obstet Gynecol 1983; 145:591.</a></li><li><a class="nounderline abstract_t">Zhao P, Lu Y, Huang W, et al. Total hysterectomy versus uterine evacuation for preventing post-molar gestational trophoblastic neoplasia in patients who are at least 40 years old: a systematic review and meta-analysis. BMC Cancer 2019; 19:13.</a></li><li><a class="nounderline abstract_t">Tidy JA, Gillespie AM, Bright N, et al. Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy. Gynecol Oncol 2000; 78:309.</a></li><li><a class="nounderline abstract_t">Ramos MM, Maesta I, de Araújo Costa RA, et al. Clinical characteristics and thyroid function in complete hydatidiform mole complicated by hyperthyroidism. Gynecol Oncol 2022; 165:137.</a></li><li><a class="nounderline abstract_t">Pereira JV, Lim T. Hyperthyroidism in gestational trophoblastic disease - a literature review. Thyroid Res 2021; 14:1.</a></li><li><a class="nounderline abstract_t">Ottanelli S, Simeone S, Serena C, et al. PP120. Hydatidiform mole as a cause of eclampsia in the first trimester: A case report. Pregnancy Hypertens 2012; 2:304.</a></li><li><a class="nounderline abstract_t">Adali E, Kurdoglu M, Avcu S, et al. Reversible acute cortical blindness associated with eclampsia in complete hydatidiform mole. Ir J Med Sci 2011; 180:287.</a></li><li><a class="nounderline abstract_t">Padrón L, Rezende Filho J, Amim Junior J, et al. Manual Compared With Electric Vacuum Aspiration for Treatment of Molar Pregnancy. Obstet Gynecol 2018; 131:652.</a></li><li><a class="nounderline abstract_t">Braga A, Padrón L, Rezende-Filho J, et al. Treatment of hydatidiform mole using manual vacuum aspiration: technical and tactical aspects. Int J Gynecol Cancer 2021; 31:1299.</a></li><li><a class="nounderline abstract_t">Ngan HYS, Seckl MJ, Berkowitz RS, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet 2021; 155 Suppl 1:86.</a></li><li><a class="nounderline abstract_t">Tse KY, Chan KK, Tam KF, Ngan HY. 20-year experience of managing profuse bleeding in gestational trophoblastic disease. J Reprod Med 2007; 52:397.</a></li><li class="breakAll">Elias KM, Horowitz NS, Berkowitz RS. Presentation and management of molar pregnancy. In: Gestational Trophoblastic Disease, 5th ed, Hancock BW, Seckl MS, Berkowitz RS (Eds), International Society for the Study of Trophoblastic Diseases, 2022.</li><li><a class="nounderline abstract_t">Yamamoto E, Nishino K, Niimi K, et al. Evaluation of a routine second curettage for hydatidiform mole: a cohort study. Int J Clin Oncol 2020; 25:1178.</a></li><li><a class="nounderline abstract_t">Sugrue R, Foley O, Elias KM, et al. Outcomes of minimally invasive versus open abdominal hysterectomy in patients with gestational trophoblastic disease. Gynecol Oncol 2021; 160:445.</a></li><li><a class="nounderline abstract_t">Patel M, Stuparich M, Nahas S. Total laparoscopic hysterectomy in combination with dilation and evacuation of an 18-week-sized uterus with gestational trophoblastic neoplasia: a novel treatment approach. Am J Obstet Gynecol 2021; 224:314.</a></li><li><a class="nounderline abstract_t">Applebaum J, Mulugeta-Gordon L, Mokkarala S, Salva CR. Perioperative Considerations for Hysterectomy in Second-Trimester Molar Pregnancy. Obstet Gynecol 2023; 142:211.</a></li><li><a class="nounderline abstract_t">Soto-Wright V, Bernstein M, Goldstein DP, Berkowitz RS. The changing clinical presentation of complete molar pregnancy. Obstet Gynecol 1995; 86:775.</a></li><li><a class="nounderline abstract_t">Braga A, Moraes V, Maestá I, et al. Changing Trends in the Clinical Presentation and Management of Complete Hydatidiform Mole Among Brazilian Women. Int J Gynecol Cancer 2016; 26:984.</a></li><li><a class="nounderline abstract_t">Twiggs LB, Morrow CP, Schlaerth JB. Acute pulmonary complications of molar pregnancy. Am J Obstet Gynecol 1979; 135:189.</a></li><li><a class="nounderline abstract_t">Berkowitz RS, Goldstein DP, Bernstein MR. Laparoscopy in the management of gestational trophoblastic neoplasms. J Reprod Med 1980; 24:261.</a></li><li><a class="nounderline abstract_t">Wang Q, Fu J, Hu L, et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2017; 9:CD007289.</a></li><li><a class="nounderline abstract_t">Biswas J, Dasgupta S, Datta M, et al. Effect of single-dose methotrexate injection to prevent neoplastic changes in high risk complete hydatidiform mole: A randomised control trial. J Family Med Prim Care 2022; 11:6036.</a></li><li><a class="nounderline abstract_t">Kashimura Y, Kashimura M, Sugimori H, et al. Prophylactic chemotherapy for hydatidiform mole. Five to 15 years follow-up. Cancer 1986; 58:624.</a></li><li><a class="nounderline abstract_t">Berkowitz RS, Goldstein DP, DuBeshter B, Bernstein MR. Management of complete molar pregnancy. J Reprod Med 1987; 32:634.</a></li><li><a class="nounderline abstract_t">Massad LS, Abu-Rustum NR, Lee SS, Renta V. Poor compliance with postmolar surveillance and treatment protocols by indigent women. Obstet Gynecol 2000; 96:940.</a></li><li><a class="nounderline abstract_t">Victoria Diniz M, Sun SY, Barsottini C, et al. Experience With the Use of an Online Community on Facebook for Brazilian Patients With Gestational Trophoblastic Disease: Netnography Study. J Med Internet Res 2018; 20:e10897.</a></li><li class="breakAll">https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/appendixd.html (Accessed on July 22, 2019).</li><li><a class="nounderline abstract_t">Dantas PRS, Maestá I, Filho JR, et al. Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors? Gynecol Oncol 2017; 147:364.</a></li><li><a class="nounderline abstract_t">Wolfberg AJ, Berkowitz RS, Goldstein DP, et al. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy. Obstet Gynecol 2005; 106:548.</a></li><li><a class="nounderline abstract_t">Tuncer ZS, Bernstein MR, Goldstein DP, et al. Outcome of pregnancies occurring within 1 year of hydatidiform mole. Obstet Gynecol 1999; 94:588.</a></li><li><a class="nounderline abstract_t">Wolfberg AJ, Feltmate C, Goldstein DP, et al. Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy. Obstet Gynecol 2004; 104:551.</a></li><li><a class="nounderline abstract_t">Wolfberg AJ, Growdon WB, Feltmate CM, et al. Low risk of relapse after achieving undetectable HCG levels in women with partial molar pregnancy. Obstet Gynecol 2006; 108:393.</a></li><li><a class="nounderline abstract_t">Kerkmeijer LG, Wielsma S, Massuger LF, et al. Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands. Gynecol Oncol 2007; 106:142.</a></li><li><a class="nounderline abstract_t">Lavie I, Rao GG, Castrillon DH, et al. Duration of human chorionic gonadotropin surveillance for partial hydatidiform moles. Am J Obstet Gynecol 2005; 192:1362.</a></li><li><a class="nounderline abstract_t">Sebire NJ, Foskett M, Short D, et al. Shortened duration of human chorionic gonadotrophin surveillance following complete or partial hydatidiform mole: evidence for revised protocol of a UK regional trophoblastic disease unit. BJOG 2007; 114:760.</a></li><li><a class="nounderline abstract_t">Schmitt C, Doret M, Massardier J, et al. Risk of gestational trophoblastic neoplasia after hCG normalisation according to hydatidiform mole type. Gynecol Oncol 2013; 130:86.</a></li><li><a class="nounderline abstract_t">Braga A, Maestá I, Matos M, et al. Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation. Gynecol Oncol 2015; 139:283.</a></li><li><a class="nounderline abstract_t">Coyle C, Short D, Jackson L, et al. What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients. Gynecol Oncol 2018; 148:254.</a></li><li><a class="nounderline abstract_t">Ngan HYS, Seckl MJ, Berkowitz RS, et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet 2018; 143 Suppl 2:79.</a></li><li class="breakAll">NCCN Clinical practice guidelines in oncology. Gestational trophoblastic neoplasia. version 1.2020. December 11, 2019. https://www.nccn.org/professionals/physician_gls/pdf/gtn.pdf (Accessed on January 08, 2020).</li><li><a class="nounderline abstract_t">Growdon WB, Wolfberg AJ, Feltmate CM, et al. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia among women with partial molar pregnancies. J Reprod Med 2006; 51:871.</a></li><li><a class="nounderline abstract_t">Gockley AA, Lin LH, Davis M, et al. Impact of clinical characteristics on human chorionic gonadotropin regression after molar pregnancy. Clinics (Sao Paulo) 2021; 76:e2830.</a></li><li><a class="nounderline abstract_t">Albright BB, Shorter JM, Mastroyannis SA, et al. Gestational Trophoblastic Neoplasia After Human Chorionic Gonadotropin Normalization Following Molar Pregnancy: A Systematic Review and Meta-analysis. Obstet Gynecol 2020; 135:12.</a></li><li><a class="nounderline abstract_t">Horowitz NS, Berkowitz RS, Elias KM. Considering Changes in the Recommended Human Chorionic Gonadotropin Monitoring After Molar Evacuation. Obstet Gynecol 2020; 135:9.</a></li><li><a class="nounderline abstract_t">Agarwal R, Teoh S, Short D, et al. Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study. Lancet 2012; 379:130.</a></li><li><a class="nounderline abstract_t">Braga A, Torres B, Burlá M, et al. Is chemotherapy necessary for patients with molar pregnancy and human chorionic gonadotropin serum levels raised but falling at 6months after uterine evacuation? Gynecol Oncol 2016; 143:558.</a></li><li><a class="nounderline abstract_t">FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet 2009; 105:3.</a></li><li><a class="nounderline abstract_t">Kohorn EI. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment. Int J Gynecol Cancer 2001; 11:73.</a></li><li><a class="nounderline abstract_t">Cole LA. Hyperglycosylated hCG, a review. Placenta 2010; 31:653.</a></li><li><a class="nounderline abstract_t">Kohorn EI. What we know about low-level hCG: definition, classification and management. J Reprod Med 2004; 49:433.</a></li><li><a class="nounderline abstract_t">Ngu SF, Chan KK. Management of Chemoresistant and Quiescent Gestational Trophoblastic Disease. Curr Obstet Gynecol Rep 2014; 3:84.</a></li><li><a class="nounderline abstract_t">Cole LA, Khanlian SA. Inappropriate management of women with persistent low hCG results. J Reprod Med 2004; 49:423.</a></li><li><a class="nounderline abstract_t">Cole LA, Muller CY. Hyperglycosylated hCG in the management of quiescent and chemorefractory gestational trophoblastic diseases. Gynecol Oncol 2010; 116:3.</a></li><li><a class="nounderline abstract_t">Hancock BW. hCG measurement in gestational trophoblastic neoplasia: a critical appraisal. J Reprod Med 2006; 51:859.</a></li><li><a class="nounderline abstract_t">Berkowitz RS, Goldstein DP. Clinical practice. Molar pregnancy. N Engl J Med 2009; 360:1639.</a></li><li><a class="nounderline abstract_t">Tow WS. The influence of the primary treatment of hydatidiform mole on its subsequent course. J Obstet Gynaecol Br Commonw 1966; 73:544.</a></li><li><a class="nounderline abstract_t">Xia ZF, Song HZ, Tang MY. Risk of malignancy and prognosis using a provisional scoring system in hydatidiform mole. Chin Med J (Engl) 1980; 93:605.</a></li><li><a class="nounderline abstract_t">Tsukamoto N, Iwasaka T, Kashimura Y, et al. Gestational trophoblastic disease in women aged 50 or more. Gynecol Oncol 1985; 20:53.</a></li><li><a class="nounderline abstract_t">Tsuji K, Yagi S, Nakano R. Increased risk of malignant transformation of hydatidiform moles in older gravidas: a cytogenetic study. Obstet Gynecol 1981; 58:351.</a></li><li><a class="nounderline abstract_t">Martin DA, Sutton GP, Ulbright TM, et al. DNA content as a prognostic index in gestational trophoblastic neoplasia. Gynecol Oncol 1989; 34:383.</a></li><li><a class="nounderline abstract_t">Braga A, Growdon WB, Bernstein M, et al. Molar pregnancy in adolescents. J Reprod Med 2012; 57:225.</a></li><li><a class="nounderline abstract_t">Czernobilsky B, Barash A, Lancet M. Partial moles: a clinicopathologic study of 25 cases. Obstet Gynecol 1982; 59:75.</a></li><li><a class="nounderline abstract_t">Feltmate CM, Growdon WB, Wolfberg AJ, et al. Clinical characteristics of persistent gestational trophoblastic neoplasia after partial hydatidiform molar pregnancy. J Reprod Med 2006; 51:902.</a></li><li><a class="nounderline abstract_t">Wielsma S, Kerkmeijer L, Bekkers R, et al. Persistent trophoblast disease following partial molar pregnancy. Aust N Z J Obstet Gynaecol 2006; 46:119.</a></li><li><a class="nounderline abstract_t">Wong LC, Ma HK. The syndrome of partial mole. Arch Gynecol 1984; 234:161.</a></li><li><a class="nounderline abstract_t">Ohama K, Ueda K, Okamoto E, et al. Cytogenetic and clinicopathologic studies of partial moles. Obstet Gynecol 1986; 68:259.</a></li><li><a class="nounderline abstract_t">Bolis G, Belloni C, Bonazzi C, et al. Analysis of 309 cases after hydatidiform mole: different follow-up program according to biologic behavior. Tumori 1988; 74:93.</a></li><li><a class="nounderline abstract_t">Seckl MJ, Fisher RA, Salerno G, et al. Choriocarcinoma and partial hydatidiform moles. Lancet 2000; 356:36.</a></li><li><a class="nounderline abstract_t">Goto S, Yamada A, Ishizuka T, Tomoda Y. Development of postmolar trophoblastic disease after partial molar pregnancy. Gynecol Oncol 1993; 48:165.</a></li><li><a class="nounderline abstract_t">Hancock BW, Nazir K, Everard JE. Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome. J Reprod Med 2006; 51:764.</a></li><li><a class="nounderline abstract_t">Worley MJ Jr, Joseph NT, Berkowitz RS, Goldstein DP. Women with a partial mole during their first pregnancy and diagnosed earlier in gestation are at increased risk of developing gestational trophoblastic neoplasia. Int J Gynecol Cancer 2014; 24:941.</a></li><li><a class="nounderline abstract_t">Vargas R, Barroilhet LM, Esselen K, et al. Subsequent pregnancy outcomes after complete and partial molar pregnancy, recurrent molar pregnancy, and gestational trophoblastic neoplasia: an update from the New England Trophoblastic Disease Center. J Reprod Med 2014; 59:188.</a></li><li><a class="nounderline abstract_t">Bagshawe KD, Dent J, Webb J. Hydatidiform mole in England and Wales 1973-83. Lancet 1986; 2:673.</a></li><li><a class="nounderline abstract_t">Sebire NJ, Fisher RA, Foskett M, et al. Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy. BJOG 2003; 110:22.</a></li><li><a class="nounderline abstract_t">BRANDES J, PERETZ A. RECURRENT HYDATIDIFORM MOLE; REPORT OF A CASE. Obstet Gynecol 1965; 25:398.</a></li><li><a class="nounderline abstract_t">Rice LW, Lage JM, Berkowitz RS, et al. Repetitive complete and partial hydatidiform mole. Obstet Gynecol 1989; 74:217.</a></li><li><a class="nounderline abstract_t">Parazzini F, Mangili G, Belloni C, et al. The problem of identification of prognostic factors for persistent trophoblastic disease. Gynecol Oncol 1988; 30:57.</a></li><li><a class="nounderline abstract_t">Braga A, Andrade T, do Carmo Borges de Souza M, et al. Presentation, medical complications and development of gestational trophoblastic neoplasia of hydatidiform mole after intracytoplasmic sperm injection as compared to hydatidiform mole after spontaneous conception - a retrospective cohort study and literature review. Gynecol Oncol 2023; 170:179.</a></li><li><a class="nounderline abstract_t">Bambaranda BGIK, Bomiriya R, Mehlawat P, Choudhary M. Association of extended culture to blastocyst and pre-malignant gestational trophoblastic disease risk following IVF/ICSI-assisted reproduction cycles: an analysis of large UK national database. J Assist Reprod Genet 2022; 39:2317.</a></li><li><a class="nounderline abstract_t">Baasanjav B, Usui H, Kihara M, et al. The risk of post-molar gestational trophoblastic neoplasia is higher in heterozygous than in homozygous complete hydatidiform moles. Hum Reprod 2010; 25:1183.</a></li><li><a class="nounderline abstract_t">Hajri T, Massoud M, Vergne M, et al. Multiple pregnancy with complete hydatidiform mole and coexisting normal fetus in a retrospective cohort of 141 patients. Am J Obstet Gynecol 2023.</a></li><li><a class="nounderline abstract_t">Lin LH, Maestá I, Braga A, et al. Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: A retrospective multicenter cohort and literature review. Gynecol Oncol 2017; 145:88.</a></li></ol></div><div id="topicVersionRevision">Topic 3194 Version 44.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/188340" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hydatidiform mole: two entities. A morphologic and cytogenetic study with some clinical consideration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7070731" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The clinicopathologic profile of the partial hydatidiform mole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/686053" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The syndromes of hydatidiform mole. I. Cytogenetic and morphologic correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22846466" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Current advances in the management of gestational trophoblastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26050078" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Invasive mole in a perimenopausal woman: a case report and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22696822" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Complete hydatidiform mole in women aged 40 to 49 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20626176" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Complete hydatidiform mole in women older than age 50.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6829636" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Natural history of hydatidiform mole after primary evacuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30612545" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Total hysterectomy versus uterine evacuation for preventing post-molar gestational trophoblastic neoplasia in patients who are at least 40 years old: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10985885" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35153074" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical characteristics and thyroid function in complete hydatidiform mole complicated by hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33446242" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hyperthyroidism in gestational trophoblastic disease - a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26105442" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : PP120. Hydatidiform mole as a cause of eclampsia in the first trimester: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19562410" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Reversible acute cortical blindness associated with eclampsia in complete hydatidiform mole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29528932" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Manual Compared With Electric Vacuum Aspiration for Treatment of Molar Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34049976" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Treatment of hydatidiform mole using manual vacuum aspiration: technical and tactical aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34669197" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Diagnosis and management of gestational trophoblastic disease: 2021 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17583238" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : 20-year experience of managing profuse bleeding in gestational trophoblastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17583238" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : 20-year experience of managing profuse bleeding in gestational trophoblastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32144509" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Evaluation of a routine second curettage for hydatidiform mole: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33272644" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Outcomes of minimally invasive versus open abdominal hysterectomy in patients with gestational trophoblastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33197418" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Total laparoscopic hysterectomy in combination with dilation and evacuation of an 18-week-sized uterus with gestational trophoblastic neoplasia: a novel treatment approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37348096" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Perioperative Considerations for Hysterectomy in Second-Trimester Molar Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7566847" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The changing clinical presentation of complete molar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26905335" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Changing Trends in the Clinical Presentation and Management of Complete Hydatidiform Mole Among Brazilian Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/474670" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Acute pulmonary complications of molar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6252319" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Laparoscopy in the management of gestational trophoblastic neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28892119" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36618146" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of single-dose methotrexate injection to prevent neoplastic changes in high risk complete hydatidiform mole: A randomised control trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3015368" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prophylactic chemotherapy for hydatidiform mole. Five to 15 years follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3312599" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Management of complete molar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11084182" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Poor compliance with postmolar surveillance and treatment protocols by indigent women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30249575" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Experience With the Use of an Online Community on Facebook for Brazilian Patients With Gestational Trophoblastic Disease: Netnography Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30249575" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Experience With the Use of an Online Community on Facebook for Brazilian Patients With Gestational Trophoblastic Disease: Netnography Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28927899" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135585" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10511364" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Outcome of pregnancies occurring within 1 year of hydatidiform mole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15339768" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16880311" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Low risk of relapse after achieving undetectable HCG levels in women with partial molar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17462723" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15902109" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Duration of human chorionic gonadotropin surveillance for partial hydatidiform moles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17516969" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Shortened duration of human chorionic gonadotrophin surveillance following complete or partial hydatidiform mole: evidence for revised protocol of a UK regional trophoblastic disease unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23523617" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Risk of gestational trophoblastic neoplasia after hCG normalisation according to hydatidiform mole type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26383828" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29229282" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30306586" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Update on the diagnosis and management of gestational trophoblastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30306586" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Update on the diagnosis and management of gestational trophoblastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17165432" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Postevacuation hCG levels and risk of gestational trophoblastic neoplasia among women with partial molar pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34468539" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Impact of clinical characteristics on human chorionic gonadotropin regression after molar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31809433" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Gestational Trophoblastic Neoplasia After Human Chorionic Gonadotropin Normalization Following Molar Pregnancy: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31809444" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Considering Changes in the Recommended Human Chorionic Gonadotropin Monitoring After Molar Evacuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22130490" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27640962" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Is chemotherapy necessary for patients with molar pregnancy and human chorionic gonadotropin serum levels raised but falling at 6months after uterine evacuation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19322933" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11285037" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20619452" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Hyperglycosylated hCG, a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15283049" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : What we know about low-level hCG: definition, classification and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24533232" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Management of Chemoresistant and Quiescent Gestational Trophoblastic Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15283048" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Inappropriate management of women with persistent low hCG results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19822356" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Hyperglycosylated hCG in the management of quiescent and chemorefractory gestational trophoblastic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17165429" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : hCG measurement in gestational trophoblastic neoplasia: a critical appraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19369669" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Clinical practice. Molar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5950115" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The influence of the primary treatment of hydatidiform mole on its subsequent course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6775895" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Risk of malignancy and prognosis using a provisional scoring system in hydatidiform mole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2981190" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Gestational trophoblastic disease in women aged 50 or more.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7266955" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Increased risk of malignant transformation of hydatidiform moles in older gravidas: a cytogenetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2548937" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : DNA content as a prognostic index in gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22696817" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Molar pregnancy in adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7078853" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Partial moles: a clinicopathologic study of 25 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17165438" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Clinical characteristics of persistent gestational trophoblastic neoplasia after partial hydatidiform molar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16638033" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Persistent trophoblast disease following partial molar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6203492" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The syndrome of partial mole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2426638" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Cytogenetic and clinicopathologic studies of partial moles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2451334" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Analysis of 309 cases after hydatidiform mole: different follow-up program according to biologic behavior.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10892763" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Choriocarcinoma and partial hydatidiform moles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8428686" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Development of postmolar trophoblastic disease after partial molar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17086803" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24819660" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Women with a partial mole during their first pregnancy and diagnosed earlier in gestation are at increased risk of developing gestational trophoblastic neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24937955" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Subsequent pregnancy outcomes after complete and partial molar pregnancy, recurrent molar pregnancy, and gestational trophoblastic neoplasia: an update from the New England Trophoblastic Disease Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2876145" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Hydatidiform mole in England and Wales 1973-83.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12504931" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14268024" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : RECURRENT HYDATIDIFORM MOLE; REPORT OF A CASE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2748058" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Repetitive complete and partial hydatidiform mole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2835296" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The problem of identification of prognostic factors for persistent trophoblastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36706644" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Presentation, medical complications and development of gestational trophoblastic neoplasia of hydatidiform mole after intracytoplasmic sperm injection as compared to hydatidiform mole after spontaneous conception - a retrospective cohort study and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36001210" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Association of extended culture to blastocyst and pre-malignant gestational trophoblastic disease risk following IVF/ICSI-assisted reproduction cycles: an analysis of large UK national database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20208060" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The risk of post-molar gestational trophoblastic neoplasia is higher in heterozygous than in homozygous complete hydatidiform moles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37722570" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Multiple pregnancy with complete hydatidiform mole and coexisting normal fetus in a retrospective cohort of 141 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28132722" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: A retrospective multicenter cohort and literature review.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
